La prophylaxie neuro-méningéedans les lymphomes B diffus à grandes cellules.
Mots-clés :
lymphome, rechuteneuro-méningée, facteurs derisque, prophylaxieRésumé
La rechute neuro-méningée des lymphomes B diffus à grandes cellules constitue une complication rare avec un pronostic réservé à cause d’une mortalité précoce. Certains facteurs de risque sont associés à un risque accru de rechute neuro-méningée :LDH élevées, plus d’une atteinte extranodale et l’atteinte de certains sites anatomiques. La place et les modalités de la prophylaxie neuro-méningée est un sujet de discussion encore controversé.De ce fait et à travers une revue de la littérature on propose de préciser l’intérêt et les modalités de la prophylaxie neuro-méningée aucours du traitement des lymphomes B diffus à grandes cellules.
Téléchargements
Références
Mead GM, Kennedy P, SmithJL et al. Involvement of the central nervous system by non-Hodgkin's lymphoma in adults. A review of 36 cases. Q J Med 1986; 60:699-714.
Doolittle ND, Abrey LE, ShenkierTN et al. Brain parenchyma involvement as isolated central nervous system (CNS) relapse of systemic non-Hodgkin lymphoma: An international Primary CNS Lymphoma Collaborative Group report. Blood 2008; 111:1085-93.
Van Horn A. Lymphomatous Meningitis: Early Diagnosis and treatment. ClinJOncolNurs 2009;13:90-4.
Zhang J, Chen B, XuX. Impact of Rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: A systematic review and meta-analysis. Leuk Lymphoma 2014; 55:509-14.
Boehme V, Zeynalova S, Kloess M et al.Incidence and risk factors of central nervous system recurrence in aggressive Lymphoma- a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007; 18:149-57.
Tilly H, Lepage E, Coiffier Bet al.Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102:4284-9.
Feugier P, Virion JM, TillyH et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of Rituximab. Ann Oncol 2004; 15:129-33.
Haioun C, Besson C, Lepage E et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Ann Oncol 2000; 11:685-90.
Arkenau HT, Chong G, Cunningham D et al.The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol 2007; 18:541-5.
Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI.Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: A 20 year follow-up analysis of SWOG 8516-The Southwest Oncology Group. JClin Oncol 2009; 27:114-9.
Abhimanyu G, Harold Kunal E, Gunjan G, Mahender Y, Rin K, Tahir L.Secondary CNS relapse in DLBCL in the Rituximab Era- An analysis of Prospective studies. Blood 2014, 124:1644.
Boehme V, Schmitz N, Zeynalova S, Loeffler M, PfreundschuhM.CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHO-P14) with or without rituximab: An analysis of patients treated in the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009; 113:3896-902.
Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ.Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: The impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 2010; 21:1046-52.
Shimazu Y, Notohara K, Ueda Y. Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. Int J Hematol 2009; 89:577-83.
Cai QQ, Hu LY, GengQR et al.New risk factors and new tendency for centralnervous system relapse in patients with diffuse large B- cell lymphoma: a retrospective study. Chin J Cancer 2016; 35:87.
Mitrovic Z, Bast M, BiermanPJ et al.The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma. Br J Haematol 2012; 157:401-3.
Zucca E, Roggero E, Bertoni F et al.Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites. Ann Oncol, 1999; 10:1023-33.
Liang R, Chin E, LokeSL. Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors. Hematol Oncol 1990; 8:141-5.
Gholam D, Bibeau F, El Weshi A, Bosq J, Ribrag V. Primary breast lymphoma. Leuk Lymphoma 2003; 44:1173-8.
McMillan A, ARDESHNA KM, CWYNARSKI K, LYTTELTON M, MckayP, MONTOLO S. Guideline of the prevention of secondary central nervous system lymphoma. British committee for standards in haematology.Br J Haematol 2013; 163:168-81.
Van Besien K, Ha CS, Murphy Set al. Risk factors, treatment and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblasticlymphoma. Blood 1998; 91:1178-84.
Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol.2002; 13:1099-107.
Chihara D, Oki Y, Matsuo K et al.Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model.Leuk Lymphoma 2011; 52:2270-5.
Nitta H, Termi Y, Yokoyama M et al.Absolute Peripheral monocyte count at diagnosis predicts central nervous system relapse in diffuse large B- cell lymphoma. Haematologica 2014; 100: 87- 90.
Aukema SM, Siebert R, SchuuringE et al.Double- hit B cell lymphomas. Blood 2011; 117:2319- 31.
Kridel R, Dictrich PY. Prevention of CNS relapse in diffuse large B- cell lymphoma. Lancet Oncol 2011; 12: 1258- 66.
Schmitz N, Zeynalova S, GlassBet al.CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group.Ann Oncol 2012;23: 1267-73.
Safar V. Prophylaxie neuro-méningée dans le lymphoma B diffuse à grandes cellules: quand et comment? Horizons Hémato 2015 ;5(3) :175-6
Fletcher CD, KahlBS. Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era. Leuk lymphoma 2014; 55 (10):2228-40.
Tomita N, Kodama F, Kanamori H, Motomura S, IshigatsuboY. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-Hodgkin lymphoma. Cancer 2002; 95:576-80.
Vitolo U, Chiapella A, Ferreri AJ et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP,CNS prophylaxis and controlateral testis irradiation: final results of an international phase II trial. JClin Oncol 2011, 29:2766-72.
Tai WM, Chung J, TangPL et al.Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre and post-rituximab. Ann Hematol.2011; 90: 809-18.
Kumar A, Vanderplast A, LacasceAS et al.Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: Finding from a large national database. Cancer 2012; 118:2944-51.
Spina M, Chimienti E, MartellotaF et al. Phase 2 study of intrathecal, long- acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus- related non Hodgkin lymphoma. Cancer 2010; 116: 1495- 501.
Ferreri A J, Reni M, Pasini F et al.A multicenter study of treatment of primary CNS lymphoma. Neurology 2002; 58:1513-20.
Ferreri Aj, Guerra E, RegazziM et al. Area under the curve of Methotrexate and creatinine clearance areoutcome-determining factors in primary CNS lymphomas. Br J Cancer 2004; 90:353-8.
Joerger M, FerreriAj, KrähenbühlS et al. Dosing algorithm to target a defined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. Br J ClinPharmacol 2012; 73:240-7.
Brugieres L, LeDeley Mc, RosolenA et al.Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. JCO 2009; 27:897- 903.
Abramson JS, Hellmann M, Barnes JA et al.Intra-venous methotrexate as central nervous System (CNS) prophylaxis is associated with a low risk patients with diffuse large B- cell lymphoma. Cancer 2010;116: 4283- 90.
Ferreri ASJM, Bruno-Ventre M, DonadoniG et al.Risk- tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B- cell lymphoma treated in the Rituximab era. Br J Haematol 2015; 168:654- 62.
Zahid MF, Khan N, HashmiSK et al.Central nervous system prophylaxis in diffuse large B- cell lymphoma. Eur JHaematol 2016; 97: 108- 120.
